Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-08-25 Purchase | 2022-08-25 7:37 pm | Aeglea BioTherapeutics Inc. | AGLE | Souza Marcio Director | 90,000 | $0.5608 | $50,472 | 90,000 (Direct) | View |
| 2022-06-08 Purchase | 2022-06-10 6:24 pm | Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Commercial Officer | 28,200 | $0.71 | $20,022 | 36,200 (Direct) | View |
| 2022-03-16 Purchase | 2022-03-18 06:46 am | Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO | 80,079 | $2.344 | $187,705 | 816,835 (Indirect Direct) | View |
| 2022-03-11 Purchase | 2022-03-15 6:32 pm | Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO | 144,666 | $1.942 | $280,943 | 739,756 (Indirect Direct) | View |
| 2022-03-11 Purchase | 2022-03-15 6:30 pm | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 75,000 | $2.08 | $156,000 | 165,372 (Direct) | View |
| 2021-12-09 Purchase | 2021-12-13 8:41 pm | Aeglea BioTherapeutics Inc. | AGLE | Shanafelt Armen Director | 150,000 | $3.6646 | $549,692 | 150,000 (Direct) | View |
| 2021-12-09 Purchase | 2021-12-13 8:39 pm | Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO | 53,634 | $3.7098 | $198,972 | 595,090 (Indirect Direct) | View |
| 2021-12-09 Purchase | 2021-12-13 8:37 pm | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 50,000 | $3.72 | $186,000 | 90,372 (Direct) | View |
| 2021-08-16 Purchase | 2021-08-18 5:21 pm | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 40,372 | $6.506 | $262,660 | 40,372 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-02-23 Option Award | 2023-02-24 6:25 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 550,000 | $0 | 550,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:24 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul General Counsel | 500,000 | $0 | 500,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:22 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Business Officer | 500,000 | $0 | 500,000 (Direct) | View |
| 2023-02-23 Option Award | 2023-02-24 6:20 pm | N/A 2033-02-22 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 640,000 | $0 | 640,000 (Direct) | View |
| 2022-11-14 Option Award | 2023-01-27 6:20 pm | N/A 2032-11-13 | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 25,000 | $0 | 25,000 (Direct) | View |
Ownership | 2023-01-27 6:18 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Neuman Linda L Chief Medical Officer | 0 | $0 | 140,250 (Direct) | View |
| 2022-11-29 Option Award | 2022-12-01 8:47 pm | N/A 2032-11-28 | Aeglea BioTherapeutics Inc. | AGLE | Goldberg Jeff Marc President and CEO | 1,884,838 | $0 | 1,884,838 (Direct) | View |
| 2022-08-23 Option Award | 2022-08-25 7:39 pm | N/A 2032-08-22 | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel | 130,000 | $0 | 130,000 (Direct) | View |
Ownership | 2022-08-25 7:37 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Kastenmayer James Paul Interim CEO & General Counsel | 0 | $0 | 219,000 (Direct) | View |
| 2022-08-23 Option Award | 2022-08-25 7:36 pm | N/A 2032-08-22 | Aeglea BioTherapeutics Inc. | AGLE | Sloan Leslie Chief Operating Officer | 130,000 | $0 | 130,000 (Direct) | View |
| 2022-08-23 Option Award | 2022-08-25 7:35 pm | N/A 2032-08-22 | Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Business Officer | 130,000 | $0 | 130,000 (Direct) | View |
| 2022-08-23 Option Award | 2022-08-25 7:34 pm | N/A 2032-08-22 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 130,000 | $0 | 130,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-10 06:04 am | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Lawton Alison Frances Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:22 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Shanafelt Armen Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:21 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Souza Marcio Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:19 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Smith Hunter C Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:18 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Mahatme Sandesh Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:17 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Magovcevic-Liebisch Ivana Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:15 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | LAWLIS V BRYAN Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-06-07 Option Award | 2022-06-09 9:13 pm | N/A 2032-06-06 | Aeglea BioTherapeutics Inc. | AGLE | Cox Russell J. Director | 43,000 | $0 | 43,000 (Direct) | View |
| 2022-02-17 Option Award | 2022-02-22 4:57 pm | N/A 2032-02-16 | Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO | 350,000 | $0 | 350,000 (Direct) | View |
| 2022-02-17 Option Award | 2022-02-22 4:55 pm | N/A 2032-02-16 | Aeglea BioTherapeutics Inc. | AGLE | Weber Steven VP, Controller&Princ Acctg Off | 30,000 | $0 | 30,000 (Direct) | View |
| 2022-02-17 Option Award | 2022-02-22 4:54 pm | N/A 2032-02-16 | Aeglea BioTherapeutics Inc. | AGLE | Sloan Leslie Chief Operating Officer | 180,000 | $0 | 180,000 (Direct) | View |
| 2022-02-17 Option Award | 2022-02-22 4:51 pm | N/A 2032-02-16 | Aeglea BioTherapeutics Inc. | AGLE | Hanley Jr. Michael Conick Chief Commercial Officer | 160,000 | $0 | 160,000 (Direct) | View |
| 2022-02-17 Option Award | 2022-02-22 4:50 pm | N/A 2032-02-16 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 170,000 | $0 | 170,000 (Direct) | View |
| 2018-12-28 Ownership | 2022-02-14 5:19 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Quinn Anthony G. President & CEO | 266,295 | $0 | 537,640 (Direct) | View |
| 2021-11-12 Option Award | 2021-11-16 4:34 pm | N/A 2031-11-11 | Aeglea BioTherapeutics Inc. | AGLE | Smith Hunter C Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2021-07-06 Option Award | 2021-07-08 5:12 pm | N/A 2031-07-05 | Aeglea BioTherapeutics Inc. | AGLE | Alspaugh Jonathan Chief Financial Officer | 160,000 | $0 | 160,000 (Direct) | View |